John Horkulak has been appointed executive director of Eurasian Site Operations at Celerion. Mr. Horkulak will lead efforts to expand the company's early phase capabilities through applied translational medicine in Europe and Asia.
Mr. Horkulak will focus on identifying and building partnerships with specialist early-phase organizations with access to target patient populations in Europe and Asia. He will leverage his experience from sites in Central and Eastern Europe that perform pharmacokinetic and pharmacodynamic studies in patients with hepatic and renal insufficiency, diabetes, rheumatoid arthritis as well as asthma and COPD. Mr. Horkulak will also explore new relationships to build patient access to support early clinical studies in neurodegenerative diseases, cardiovascular disease and oncology. Additionally, he will be responsible for guiding future investment in infrastructure and personnel in these regions.
Mr. Horkulak has more than 30 years of experience in drug development at both pharmaceutical companies and CROs. His expertise includes Phase I and II study operations, as well as general management. Before joining the company, Mr. Horkulak was the founder and chief executive officer of a niche CRO, Pharmacon Research GmbH, and after its successful acquisition, he was vice president of Patient Pharmacology at a leading CRO.
“We are very pleased to have John join the Drug Development Services team at Celerion,” said Fred Pritchard, vice president, Global Drug Development at Celerion. “His comprehensive knowledge and hands-on operational experience in conducting early phase studies in patients, particularly across emerging geographic regions, will complement Celerion's efforts in North America and Europe to deliver on our clients' needs for patient studies.”